Copyright © 2002 by the European Society of Cardiology.
A cardiovascular life history
a Department of Public Health, Erasmus University Rotterdam, The Netherlands
b Population Research Centre, University of Groningen, The Netherlands
revised June 19, 2001; accepted June 20, 2001
Abstract
Aims The objective of this paper is to measure the potential burden of cardiovascular disease within the original Framingham Heart Study cohort by transforming its well-described epidemiological measures into time-based health policy measures, such as life years lost to or lived with the disease.
Methods and Results We constructed multi-state life tables of the Framingham Heart Study cohort to calculate dwelling times with a history of cardiovascular disease. Age-specific probabilities determined transitions from healthy through disease to death. For this synthetic cohort, from age 50 men (women) live on average 26 (32) years; 20 (26) free of cardiovascular disease. Allowing occupancy of more than one disease state, 50-year-old males (females) live 2·9 (1·2) years with a history of myocardial infarction, 0·93 (1·2) with a history of stroke, and 0·67 (0·93) with congestive heart failure. Having ever suffered acute myocardial infarction, stroke or congestive heart failure, life expectancy is reduced by 9 (13), 12 (15) or 16 (16) years, respectively in 60-year-old men (women).
Conclusions Transforming occurrence probabilities into time-based health measures, the prevalence of cardiovascular disease is remarkable: from age 50, 20% of remaining life expectancy is lived with the disease. Such measures are integral to appropriate health planning and assessment of the potential population health value of various treatment and prevention strategies.
Key Words: Cardiovascular diseases, morbidity, mortality, population, prevention
f1 Correspondence: Anna Peeters, Department of Public Health, Faculty of Medicine and Health Sciences, Dr. Molewaterplein 50, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
References
- Dawber T, Moore F, Mann G. Measuring the risk of coronary heart disease in adult population groups. II Coronary heart disease in the Framingham study. Am J Pub Health. 1957;47:4–24
[Free Full Text] - Doyle J, Heslin A, Hilleboe H, Formel P, Korns R. Measuring the risk of coronary heart disease in adult population groups. III A prospective study of degenerative cardiovascular disease in Albany: report of three years experience I. Ischaemic heart disease. Am J Pub Health. 1957;47:25–32
[Free Full Text] - Chapman J, Goerke L, Dixon W, Loveland D, Phillips E. Measuring the risk of coronary heart disease in adult population groups IV. The clinical status of a population group in Los Angeles under observation for two or three years. Am J Pub Health. 1957;47:33–42
[Free Full Text] - Drake R, Buechley R, Breslow L. Measuring the risk of coronary heart disease in adult population groups V. An epidemiological investigation of coronary heart disease in the California health survey population. Am J Pub Health. 1957;47:43–63
[Free Full Text] - Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. Br Med J. 2000;321:1–5
[Abstract/Free Full Text] - Chalmers J, MacMahon S, Mancia G. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens. 1999;21:1009–1060[ISI][Medline]
- Hooper L, Summerbell CD, Higgins JP. Reduced or modified dietary fat for prevention of cardiovascular disease. Cochrane Database Systematic Reviews. 2000;2:CD002137
- Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction. Arch Intern Med. 2000;160:939–944
[Abstract/Free Full Text] - Lightwood J, Glantz S. Short-term economic and health benefits of smoking cessation. Myocardial infarction and stroke. Circulation. 1997;96:1089–1096
[Abstract/Free Full Text] - Anderson K, Wilson P, Odell P, Kannel W. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–362
[Free Full Text] - Kannel W, Neaton J, Wentworth D. Overall and coronary heart disease mortality rates in relation to major risk factors in 325348 men screened for the MRFIT. Am Heart J. 1986;112:825–836[CrossRef][ISI][Medline]
- Murray, C, Lopez, A, The Global Burden of Disease, Harvard, Harvard School of Public Health, 1996
- Shurtleff, D, Some characteristics related to the incidence of cardiovascular disease and death: Framingham study 16 years follow-up, Kannel, WGordon, T, The Framingham Study: An epidemiological investigation of cardiovascular disease, Washington, D.C. US Government Printing Office, 1971
- Clayton D, Schifflers E. Models for temporal variation in cancer rates I: age-period and age-cohort models. Stats Med. 1987;6:449–467[ISI][Medline]
- Willekens, F, Life table analysis of staging processes, Becker, HA, Life histories and generations, Utrecht, Rijksuniversiteit te Utrecht, 1991
- Chiang C. The life table and its applications. : Robert E Kreigler Publishing Company; 1984.
- Davis R, FD H, Lip G. ABC of heart failure. History and epidemiology. Br Med J. 2000;320:39–42
[Free Full Text] - Leaverton P, Sorlie P, Kleinman J. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chron Dis. 1987;40:775–784[CrossRef][ISI][Medline]
- Lloyd-Jones D, Larson M, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89–92[CrossRef][ISI][Medline]
- Rosamond W, Chambless L, Folsom A. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998;339:861–867
[Abstract/Free Full Text] - McGovern P, Pankow J, Shahar E. Recent trends in acute coronary heart disease. Mortality, morbidity, medical care and risk factors. N Engl J Med. 1996;334:884–890
[Abstract/Free Full Text] - Sytowski P, Kannel W, D'Agostino R. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med. 1990;322:1635–1641[Abstract]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. K. Choudhry, A. R. Patrick, E. M. Antman, J. Avorn, and W. H. Shrank Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post-Myocardial Infarction Medicare Beneficiaries Circulation, March 11, 2008; 117(10): 1261 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. H. Franco, E. W. Steyerberg, F. B. Hu, J. Mackenbach, and W. Nusselder Associations of Diabetes Mellitus With Total Life Expectancy and Life Expectancy With and Without Cardiovascular Disease Arch Intern Med, June 11, 2007; 167(11): 1145 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. H. Franco, C. de Laet, A. Peeters, J. Jonker, J. Mackenbach, and W. Nusselder Effects of Physical Activity on Life Expectancy With Cardiovascular Disease Arch Intern Med, November 14, 2005; 165(20): 2355 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Beinart, P. Kolm, E. Veledar, Z. Zhang, E. M. Mahoney, O. Bouin, S. Gabriel, J. Jackson, R. Chen, J. Caro, et al. Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial J. Am. Coll. Cardiol., September 6, 2005; 46(5): 761 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. H. Franco, A. Peeters, L. Bonneux, and C. de Laet Blood Pressure in Adulthood and Life Expectancy With Cardiovascular Disease in Men and Women: Life Course Analysis Hypertension, August 1, 2005; 46(2): 280 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Weintraub, E. M. Mahoney, A. Lamy, S. Culler, Y. Yuan, J. Caro, S. Gabriel, S. Yusuf, and CURE Study Investigators Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation J. Am. Coll. Cardiol., March 15, 2005; 45(6): 838 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Weintraub, Z. Zhang, E. M. Mahoney, P. Kolm, J. A. Spertus, J. Caro, J. Ishak, R. Goldberg, J. Tooley, R. Willke, et al. Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure Circulation, March 8, 2005; 111(9): 1106 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Cowper, K. Udayakumar, M. H. Sketch Jr, and E. D. Peterson Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention J. Am. Coll. Cardiol., February 1, 2005; 45(3): 369 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. H Franco, L. Bonneux, C. de Laet, A. Peeters, E. W Steyerberg, and J. P Mackenbach The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75% BMJ, December 18, 2004; 329(7480): 1447 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.E Diaz, H.K Graham, and A.W Trafford Enhanced sarcolemmal Ca2+ efflux reduces sarcoplasmic reticulum Ca2+ content and systolic Ca2+ in cardiac hypertrophy Cardiovasc Res, June 1, 2004; 62(3): 538 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Barrett-Connor, E.-G. V. Giardina, A. K. Gitt, U. Gudat, H. O. Steinberg, and D. Tschoepe Women and Heart Disease: The Role of Diabetes and Hyperglycemia Arch Intern Med, May 10, 2004; 164(9): 934 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Mamun, A. Peeters, J. Barendregt, F. Willekens, W. Nusselder, L. Bonneux, and for NEDCOM, The Netherlands Epidermiology and Demo Smoking decreases the duration of life lived with and without cardiovascular disease: a life course analysis of the Framingham Heart Study Eur. Heart J., March 1, 2004; 25(5): 409 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Torbey Editorial Comment--Decline in Stroke Mortality: Splitters and Lumpers Stroke, July 1, 2003; 34(7): 1615 - 1616. [Full Text] [PDF]
|
|
|
|
|
|
A. Peeters, L. Bonneux, J. J. Barendregt, and J. P. Mackenbach Improvements in Treatment of Coronary Heart Disease and Cessation of Stroke Mortality Rate Decline Stroke, July 1, 2003; 34(7): 1610 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Peeters, J. J. Barendregt, F. Willekens, J. P. Mackenbach, A. A. Mamun, L. Bonneux, and for NEDCOM, the Netherlands Epidemiology and Demog Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis Ann Intern Med, January 7, 2003; 138(1): 24 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Mahoney, C. T. Jurkovitz, H. Chu, E. R. Becker, S. Culler, A. S. Kosinski, D. H. Robertson, C. Alexander, S. Nag, J. R. Cook, et al. Cost and Cost-effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction JAMA, October 16, 2002; 288(15): 1851 - 1858. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||